Pharmaceutical organisations are becoming increasingly reliant on the data that is available to them to develop new products and overcome the modern challenges of curing diseases.
There is a large amount of information in the world that can aid the process of research and development (R&D). This has not always been openly available, largely because of Big Pharma’s desire to protect this information and maintain their competitive business edge.
This is now starting to change; businesses and organisations — both public and private — are starting to share an increasing amount of information between one another. This growing access to data is allowing organisations to apply new techniques to different areas of drug development that were not possible before: key examples being recognising disease signatures or applying the precision medicine model.
As pharmaceutical companies evolve to try to make the most out of data, the challenges they face change as well. Although open information is beneficial to the industry, utilising it is difficult.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.